2023
Global burden of disease due to rifampicin-resistant tuberculosis: a mathematical modeling analysis
Menzies N, Allwood B, Dean A, Dodd P, Houben R, James L, Knight G, Meghji J, Nguyen L, Rachow A, Schumacher S, Mirzayev F, Cohen T. Global burden of disease due to rifampicin-resistant tuberculosis: a mathematical modeling analysis. Nature Communications 2023, 14: 6182. PMID: 37794037, PMCID: PMC10550952, DOI: 10.1038/s41467-023-41937-9.Peer-Reviewed Original ResearchConceptsDisability-adjusted life yearsRifampicin-resistant tuberculosisRR-TBGlobal burdenSubstantial short-term morbidityRifampicin-susceptible tuberculosisShort-term morbidityOverall disease burdenLong-term health impactsPost-treatment careTB survivorsDisease burdenTreatment outcomesTuberculosis survivorsCase detectionLife yearsRifampicin resistanceTuberculosisHealth impactsBurdenHealth expenditureDiseaseSurvivorsMathematical modeling analysisFormer Soviet Union countries
2021
Lifetime burden of disease due to incident tuberculosis: a global reappraisal including post-tuberculosis sequelae
Menzies NA, Quaife M, Allwood BW, Byrne AL, Coussens AK, Harries AD, Marx FM, Meghji J, Pedrazzoli D, Salomon JA, Sweeney S, van Kampen SC, Wallis RS, Houben RMGJ, Cohen T. Lifetime burden of disease due to incident tuberculosis: a global reappraisal including post-tuberculosis sequelae. The Lancet Global Health 2021, 9: e1679-e1687. PMID: 34798027, PMCID: PMC8609280, DOI: 10.1016/s2214-109x(21)00367-3.Peer-Reviewed Original ResearchConceptsPost-tuberculosis sequelaeBurden estimatesTuberculosis diseaseDisease episodesIncident tuberculosisIncident tuberculosis casesIncident tuberculosis diseaseNon-fatal health lossOverall disease burdenPulmonary tuberculosis diseaseLifetime health outcomesDisease burden estimatesElevated mortality riskHigh incidence rateExtrapulmonary diseaseLung functionCase fatalityHIV statusLifetime burdenTuberculosis casesTotal DALYsDisease burdenIncidence rateHypothetical cohortTuberculosis survivors